Article
Mesothelioma Diagnostic Test that Predicts Survival Now Available
Validation studies presented at the annual meeting of the American Association for Thoracic Surgery push availability of the DecisionDx-Mesothelioma molecular test through an early access program.
th
Castle Biosciences Inc. announced that data from two validation studies of its DecisionDx-Mesothelioma molecular test were presented at the American Association for Thoracic Surgery 94 Annual Meeting. According to the data, the test accurately predicted survival in metastatic pleural mesothelioma (MPM) patients based on the gene expression profile signature of their tumor combined with clinical characteristics.
The results were reviewed during an oral presentation by Dr. Assunta De Rienzo, Ph.D., co-Director of the Thoracic Surgery Laboratory in the Department of Surgery, Thoracic Division, Brigham and Women's Hospital. The test, which combines the results of a gene expression profile with lymph node status and histology subtypes, had previously been validated in a prospective, single-center study. Following licensing of the technology from Brigham and Women's Hospital, CAP-accredited and CLIA-certified laboratory protocols were developed and validated in formalin-fixed paraffin embedded (FFPE) tissue. These results were from a second clinical validation study, which was conducted using a prospectively-planned, multi-center cohort study in conjunction with the National Mesothelioma Virtual Tissue Bank.
Read the report here: http://yhoo.it/1hdEKgp
Source: Yahoo finance
